Adaptive Biotechnologies (ADPT) Long-Term Investments (2019 - 2026)

Adaptive Biotechnologies has reported Long-Term Investments for 7 years, with the latest figure at $18.9 million in Q1 2026.

• Quarterly Long-Term Investments fell 52.0% year-over-year to $18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.9 million (down 52.0% YoY) and the FY2025 annual result came in at $13.2 million, down 60.68% from the prior year.
• Long-Term Investments climbed to $18.9 million in Q1 2026 per ADPT's latest filing, from $13.2 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $137.1 million in Q1 2022 and troughed at $4.0 million in Q3 2025.
• A 4-year average of $38.1 million and a median of $24.0 million in 2024 frame the typical range for Long-Term Investments.
• The widest YoY moves for Long-Term Investments: up 346.79% in 2022, down 90.94% in 2022.
• Over 4 years, Long-Term Investments stood at $19.7 million in 2022, then jumped by 70.88% to $33.7 million in 2024, then sank by 60.68% to $13.2 million in 2025, then soared by 42.73% to $18.9 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $18.9 million, $13.2 million, and $4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.